國家衛生研究院 NHRI:Item 3990099045/11361
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 911148      在线人数 : 950
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11361


    题名: The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    作者: Mercade, TM;Wang-Gillam, A;Chen, L;Blanc, J;Lee, K;Bodoky, G;Dean, A;Chen, J;Mirakhur, B;Siveke, J;de Jong, F
    贡献者: National Institute of Cancer Research
    摘要: Introduction: In the NAPOLI-1 phase 3 study of patients with mPDAC who progressed following gemcitabine-based therapy (NCT01494506), nal-IRIþ5-FU/LV significantly increased median overall survival (mOS) vs 5-FU/LV control (6.1 vs 4.2 months; unstratified hazard ratio [HR] 0.67 [0.49–0.92]; P ¼ 0.012). Best response to prior therapy may influence treatment outcomes, prognosis and subsequent therapy choices. Methods: This post-hoc analysis explored outcomes in NAPOLI-1 patients based on best response to prior anticancer therapy. Treatment response groups were: complete response/partial response as prior best response (CR/PR) vs not CR/PR, and complete response/partial response/stable disease as prior best response (CR/PR/SD) vs not CR/PR/SD. Results: Prior to study entry, 55/417 patients (13%) had CR/PR on prior anticancer therapy, and 211 (51%) had CR/PR/SD. In the overall intent-to-treat (ITT) population, trends towards improved outcomes were observed in CR/PR vs not CR/PR patients (mOS 5.6 vs 4.8 months, HR ¼ 0.73, P ¼ 0.08; median progression-free survival [mPFS] 3.8 vs 2.4 months, HR ¼ 0.73, P ¼ 0.06; objective response rate [ORR] 13% vs 6%, P ¼ 0.085). mOS, mPFS and ORR were similar in CR/PR/SD vs not CR/PR/SD patients (mOS 4.9 vs 4.9 months, HR ¼ 0.95, P ¼ 0.68; mPFS 2.5 vs 2.6 months, HR ¼ 1.00, P ¼ 0.95; ORR 7% vs 7%, P ¼ 1.00). In the nal-IRIþ5-FU/LV arm, a trend towards improved mOS, mPFS and ORR was observed in patients with CR/PR (n ¼ 11) vs not CR/PR (n ¼ 106) (mOS 9.3 vs 6.1 months, HR ¼ 0.64, P ¼ 0.34; mPFS 4.2 vs 3.0 months, HR ¼ 0.53, P ¼ 0.13; ORR 27% vs 15%). mOS, mPFS and ORR were similar in patients with CR/PR/SD (n ¼ 58) vs not CR/PR/SD (n ¼ 59) (mOS 6.2 vs 6.1 months, HR ¼ 1.04, P ¼ 0.88; mPFS 4.0 vs 3.3 months, HR ¼ 1.18, P ¼ 0.45; ORR 14% vs 19%, P ¼ 0.62). Patients with CR/PR numerically benefited from treatment with nal IRIþ5 FU/LV (n ¼ 11) vs 5 FU/LV (n ¼ 21) (mOS 9.3 vs 5.1 months, HR ¼ 0.46, P ¼ 0.14; mPFS 4.2 vs 1.4 months, HR ¼ 0.33, P ¼ 0.03; ORR 27% vs 0, P ¼ 0.03). Patients with not CR/PR also benefited from treatment with nal IRIþ5-FU/LV (n ¼ 106) vs 5-FU/LV (n ¼ 98) (mOS 6.1 vs 4.0 months, HR ¼ 0.69, P ¼ 0.03; mPFS 3.0 vs 1.5 months, HR ¼ 0.58, P < 0.01; ORR 15% vs 1%, P < 0.01). Similar trends towards improved outcomes were also observed in patients with CR/PR/SD when treated with nal-IRIþ5-FU/LV (n ¼ 58) vs 5-FU/LV (n ¼ 61) (mOS 6.2 vs 4.8 months, HR ¼ 0.68, P ¼ 0.09; mPFS 4.0 vs 1.4 months, HR ¼ 0.53, P < 0.01; ORR 14% vs 2%, P < 0.05). A treatment benefit was observed for patients with not CR/PR/SD when treated with nal IRIþ5-FU/LV (n ¼ 59) vs 5-FU/LV (n ¼ 58) (mOS 6.1 vs 3.6 months, HR ¼ 0.63, P ¼ 0.04; mPFS 3.3 vs 1.6 months, HR ¼ 0.56, P < 0.01; ORR 19% vs 0%, P < 0.01). Conclusion: In both the overall ITT NAPOLI-1 population and the nal-IRIþ5-FU/LV arms, there was a trend towards improved efficacy outcomes in patients with CR/PR vs not CR/PR, however this trend was not observed in CR/PR/SD vs not CR/PR/SD patients. Patients in all treatment response subgroups benefited from treatment with nal-IRIþ5-FU/LV vs 5-FU/LV, regardless of best response to prior therapy.
    日期: 2018-06
    關聯: Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152.
    Link to: https://doi.org/10.1093/annonc/mdy151.151
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000439970900192
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081592283
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000439970900192.pdf72KbAdobe PDF225检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈